FIB-4 index is associated with hepatocellular carcinoma risk in HIV-infected patients
- PMID: 22028407
- PMCID: PMC3237927
- DOI: 10.1158/1055-9965.EPI-11-0582
FIB-4 index is associated with hepatocellular carcinoma risk in HIV-infected patients
Abstract
Background: Chronic inflammation caused by hepatitis B virus infection, hepatitis C virus infection, and/or heavy alcohol use can lead to fibrosis, cirrhosis, and eventually hepatocellular carcinoma (HCC). FIB-4 is an index score calculated from platelet count, alanine transaminase, aspartate transaminase, and age that predicts fibrosis and cirrhosis. We hypothesized that high FIB-4 would be associated with development of HCC in HIV-infected persons, who are at high risk due to high prevalence of viral hepatitis and alcohol consumption, and possibly due to HIV infection itself.
Methods: Using proportional hazards models, we tested this hypothesis among 22,980 HIV-infected men from the Veterans Aging Cohort Study. We identified incident HCC cases from the Veterans Affairs Central Cancer Registry.
Results: During follow-up, there were 112 incident HCC diagnoses. The age- and race/ethnic group-adjusted HR was 4.2 [95% confidence interval (CI), 2.4-7.4] for intermediate FIB-4 and 13.0 (95% CI, 7.2-23.4) for high FIB-4, compared with low FIB-4. After further adjustment for enrollment year, CD4 count, HIV-1 RNA level, antiretroviral therapy use, hepatitis B and C virus infection, alcohol abuse/dependency, and diabetes, FIB-4 remained a strong, significant, independent risk factor for HCC. The multivariate-adjusted HR was 3.6 (95% CI, 2.1-6.4) for intermediate FIB-4 and 9.6 (95% CI, 5.2-17.4) for high FIB-4.
Conclusions: Calculated from routine, noninvasive laboratory tests, FIB-4 is a strong, independent HCC risk factor in HIV-infected patients.
Impact: FIB-4 might prove valuable as an easily measured index to identify those at highest risk for HCC, even prior to development of clinical cirrhosis.
Conflict of interest statement
Conflicts of interest: not applicable
Figures

References
-
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108. - PubMed
-
- Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER Cancer Statistics Review, 1975–2007. Bethesda, MD: National Cancer Institute; 2011.
-
- London WT, McGlynn KA. Liver Cancer. In: Scottenfeld D, Fraumeni JF, editors. Cancer Epidemiology and Prevention. New York, NY: Oxford University Press; 2006.
-
- El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterol. 2007;132:2557–76. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K01 AI070001/AI/NIAID NIH HHS/United States
- R01-AG029154/AG/NIA NIH HHS/United States
- P30 MH062294/MH/NIMH NIH HHS/United States
- U01 DA036935/DA/NIDA NIH HHS/United States
- R01 HL090342/HL/NHLBI NIH HHS/United States
- R01 AG029154/AG/NIA NIH HHS/United States
- P30-MH062294/MH/NIMH NIH HHS/United States
- U01 AI069918/AI/NIAID NIH HHS/United States
- U01 AA013566/AA/NIAAA NIH HHS/United States
- RCI-HL100347/HL/NHLBI NIH HHS/United States
- RC1 HL100347/HL/NHLBI NIH HHS/United States
- R01 HL095136/HL/NHLBI NIH HHS/United States
- R01-HL090342/HL/NHLBI NIH HHS/United States
- U01-AI069918/AI/NIAID NIH HHS/United States
- U01-AA13566/AA/NIAAA NIH HHS/United States
- U10 AA013566/AA/NIAAA NIH HHS/United States
- HL095136/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials